FEMY - Femasys: Revolutionizing Female Reproduction

• Femasys has the potential to transform both birth control and infertility, both of which are multibillion-dollar markets.
• The company has received a $50mil investment from Medtronic and more recently, existing investors bought into the IPO.
• Commercialization of FemaSeed will be helped by the fact that Femasys already has an approved product - FemaVue, on the market.
• With $33mil in cash from the IPO, Femasys should have enough cash to last for 3 years, which will potentially allow it to hit commercialization on both of its main products.

For further details see: